Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
TNFRSF8 expression
i
Other names:
TNFRSF8, TNF Receptor Superfamily Member 8, Tumor Necrosis Factor Receptor Superfamily Member 8, Lymphocyte Activation Antigen CD30, CD30L Receptor, Ki-1 Antigen, D1S166E, CD30, Tumor Necrosis Factor Receptor Superfamily, Member 8, Cytokine Receptor CD30, CD30 Antigen, TNFRSF8, Ki-1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
943
Related biomarkers:
Expression
Others
‹
TNFRSF8 positive (16)
TNFRSF8 negative (2)
TNFRSF8 overexpression (2)
CD20 expression + TNFRSF8 overexpression (1)
CD20 positive + MME positive + TNFRSF8 negative (1)
TNFRSF8 positive (16)
TNFRSF8 negative (2)
TNFRSF8 overexpression (2)
CD20 expression + TNFRSF8 overexpression (1)
CD20 positive + MME positive + TNFRSF8 negative (1)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
TNFRSF8 expression
Peripheral T-cell Lymphoma
TNFRSF8 expression
Peripheral T-cell Lymphoma
brentuximab vedotin
Sensitive: A1 - Approval
brentuximab vedotin
Sensitive
:
A1
brentuximab vedotin
Sensitive: A1 - Approval
brentuximab vedotin
Sensitive
:
A1
TNFRSF8 expression
Cutaneous T-cell Lymphoma
TNFRSF8 expression
Cutaneous T-cell Lymphoma
brentuximab vedotin
Sensitive: B - Late Trials
brentuximab vedotin
Sensitive
:
B
brentuximab vedotin
Sensitive: B - Late Trials
brentuximab vedotin
Sensitive
:
B
TNFRSF8 expression
T Cell Non-Hodgkin Lymphoma
TNFRSF8 expression
T Cell Non-Hodgkin Lymphoma
brentuximab vedotin
Sensitive: B - Late Trials
brentuximab vedotin
Sensitive
:
B
brentuximab vedotin
Sensitive: B - Late Trials
brentuximab vedotin
Sensitive
:
B
TNFRSF8 expression
Acute Myelogenous Leukemia
TNFRSF8 expression
Acute Myelogenous Leukemia
brentuximab vedotin
Sensitive: C1 - Off-label
brentuximab vedotin
Sensitive
:
C1
brentuximab vedotin
Sensitive: C1 - Off-label
brentuximab vedotin
Sensitive
:
C1
TNFRSF8 expression
Diffuse Large B Cell Lymphoma
TNFRSF8 expression
Diffuse Large B Cell Lymphoma
rituximab + brentuximab vedotin
Sensitive: C3 – Early Trials
rituximab + brentuximab vedotin
Sensitive
:
C3
rituximab + brentuximab vedotin
Sensitive: C3 – Early Trials
rituximab + brentuximab vedotin
Sensitive
:
C3
TNFRSF8 expression
Peripheral T-cell Lymphoma
TNFRSF8 expression
Peripheral T-cell Lymphoma
Sensitive: C3 – Early Trials
Sensitive
:
C3
Sensitive: C3 – Early Trials
Sensitive
:
C3
TNFRSF8 expression
Peripheral T-cell Lymphoma
TNFRSF8 expression
Peripheral T-cell Lymphoma
AFM13
Sensitive: C3 – Early Trials
AFM13
Sensitive
:
C3
AFM13
Sensitive: C3 – Early Trials
AFM13
Sensitive
:
C3
TNFRSF8 expression
Cutaneous T-cell Lymphoma
TNFRSF8 expression
Cutaneous T-cell Lymphoma
TEQ102
Sensitive: D – Preclinical
TEQ102
Sensitive
:
D
TEQ102
Sensitive: D – Preclinical
TEQ102
Sensitive
:
D
TNFRSF8 expression
Peripheral T-cell Lymphoma
TNFRSF8 expression
Peripheral T-cell Lymphoma
TEQ102
Sensitive: D – Preclinical
TEQ102
Sensitive
:
D
TEQ102
Sensitive: D – Preclinical
TEQ102
Sensitive
:
D
TNFRSF8 expression
Hodgkin Lymphoma
TNFRSF8 expression
Hodgkin Lymphoma
TEQ102
Sensitive: D – Preclinical
TEQ102
Sensitive
:
D
TEQ102
Sensitive: D – Preclinical
TEQ102
Sensitive
:
D
TNFRSF8 expression
Hematological Malignancies
TNFRSF8 expression
Hematological Malignancies
F0002-ADC
Sensitive: D – Preclinical
F0002-ADC
Sensitive
:
D
F0002-ADC
Sensitive: D – Preclinical
F0002-ADC
Sensitive
:
D
TNFRSF8 expression
Lymphoma
TNFRSF8 expression
Lymphoma
PF-08046044
Sensitive: D – Preclinical
PF-08046044
Sensitive
:
D
PF-08046044
Sensitive: D – Preclinical
PF-08046044
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login